Synthetic Studies Toward the Development of Novel Minoxidil Analogs and Conjugates with Polyamines

February 2010 in “ Tetrahedron Letters ”

George E. Magoulas, Stavros E. Bariamis, Constantinos M. Athanassopoulos, Dionissios Papaioannou

minoxidil polyamine-modified minoxidil analogs minoxidil-polyamine conjugates putrescine spermidine spermine amination N-oxidation piperidine addition N-deprotection CDI-mediated activation MNX

Studysummary This article describes the synthesis of novel polyamine-modified minoxidil analogs and conjugates to potentially enhance minoxidil's biological activity, selectivity, and water solubility, but reports no new biological results.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The document from April 1, 2010, detailed the creation of novel polyamine-modified minoxidil analogs (PMMs) and minoxidil-polyamine conjugates (MPCs) to enhance the properties of minoxidil (MNX), a drug used for treating hypertension and male pattern baldness. The study involved attaching polyamines like putrescine, spermidine, and spermine to MNX using different synthetic methods. PMMs were produced through amination, N-oxidation, piperidine addition, and N-deprotection, while MPCs were synthesized via CDI-mediated activation of MNX and coupling with protected polyamines. These new compounds showed significantly better water solubility than MNX. However, the biological effects and detailed structure-activity relationship studies were still underway at the time of publication, and there was a note of caution regarding the potential increased toxicity due to the incorporation of polyamines, particularly spermine.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

research Male Pattern Baldness: Current Treatments, Future Prospects

40 citations , July 2008 in “Drug Discovery Today”

This review addresses the limited efficacy of current treatments for male pattern baldness and explains that emerging genetic insights could lead to more effective future therapies.

research Synthesis and Characterization of Inclusion Complex of the Vasodilator Drug Minoxidil with β-Cyclodextrin

28 citations , April 2008 in “Journal of Inclusion Phenomena and Macrocyclic Chemistry”

This study identified a weak interaction between minoxidil and ß-cyclodextrin in solution, forming an inclusion complex with a 1:1 molar ratio.

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men

research A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men

142 citations , August 2007 in “Journal of The American Academy of Dermatology”

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

research Minoxidil: Mechanisms of Action on Hair Growth

397 citations , February 2004 in “British Journal of Dermatology”

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

Sulfation of Minoxidil by Multiple Human Cytosolic Sulfotransferases

research Sulfation of Minoxidil by Liver Sulfotransferase

66 citations , September 1982 in “Biochemical Pharmacology”

This study identified a sulfotransferase activity in rat liver that catalyzes the sulfation of minoxidil, contributing to its delayed hypotensive effects.